30. August 2010
Studienregister - kein Schutz vor manipulierten Studien
Beitrag im Forum Gesundheitspolitik über die Studie: Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov." Annals of Internal Medicine 153(3): 158-166. Abstract der Studie
12. August 2010
Patient & Consumer Organisations at the European Medicines Agency Financial disclosure and transparency.
HAI Europe survey reveals new data on financial transparency of patient and consumer organisations
Two-thirds of the patient and consumer organisations working with the European Medicines Agency (EMA) received partial or significant funding from pharmaceutical manufacturers and/or industry associations, which suggests that the pharmaceutical industry is the prevalent sponsor of the patient voice at the EMA.
Fewer than half of the 23 organisations complied with EMA financial reporting guidelines. The EMA appears to have failed in the monitoring and enforcement its guidelines on financial transparency.
These and other main findings are reported in HAI Europe’s recent survey on levels of financial disclosure and transparency among patient and consumer organisations at the European Medicines Agency (EMA).
Read the Research Article and Factsheet on our website www.haieurope.org
Two-thirds of the patient and consumer organisations working with the European Medicines Agency (EMA) received partial or significant funding from pharmaceutical manufacturers and/or industry associations, which suggests that the pharmaceutical industry is the prevalent sponsor of the patient voice at the EMA.
Fewer than half of the 23 organisations complied with EMA financial reporting guidelines. The EMA appears to have failed in the monitoring and enforcement its guidelines on financial transparency.
These and other main findings are reported in HAI Europe’s recent survey on levels of financial disclosure and transparency among patient and consumer organisations at the European Medicines Agency (EMA).
Read the Research Article and Factsheet on our website www.haieurope.org
8. August 2010
Avandia panel member may be investigated for possible conflicts of interest.
The US Food and Drug Administration has asked its parent department to investigate possible conflicts of interest relating to one of the members of the panel that recently recommended further restrictions on the drug rosiglitazone (marketed as Avandia), manufactured by GlaxoSmithKline (GSK) and used to control type 2 diabetes (BMJ 2010;341:c3862, 16 Jul, doi:10.1136/bmj.c3862). http://www.bmj.com/cgi/content/extract/341/aug03_2/c4083
Abonnieren
Posts (Atom)
Posts
